

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes	G protein-coupled bile acid receptor 1 (GPBAR1; TGR5)	<p>High throughput screening and canine studies identified TGR5 agonists that could help treat type 2 diabetes. Compounds targeting TGR5 increase levels of glucagon-like peptide-1 (GLP-1), which enhances insulin action. A screen of a GlaxoSmithKline plc chemical library identified isoxazole carboxamide derivatives that inhibited TGR5. Optimization of the derivatives led to two inhibitors that improved GLP-1 secretion in dogs when coadministered with glucose. GSK's next steps could include testing the compounds in additional models of diabetes.</p> <p>Intercept Pharmaceuticals Inc.'s INT-777, a TGR5 agonist, is in preclinical testing to treat diabetes and obesity.</p> <p>SciBX 2(47); doi:10.1038/scibx.2009.1727 Published online Dec. 10, 2009</p>	Patent and licensing status unavailable	<p>Evans, K. <i>et al. J. Med. Chem.</i>; published online Nov. 10, 2009; doi:10.1021/jm901434t</p> <p>Contact: Karen A. Evans, GlaxoSmithKline plc, Collegeville, Pa.</p> <p>e-mail: karen.a.evans@gsk.com</p>